Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Clin Pharmacol Ther. 2010 May;87(5):553-7. doi: 10.1038/clpt.2010.3. Epub 2010 Mar 24.
In a placebo-controlled trial, we examined the efficacy of a 6-month ("extended") transdermal nicotine therapy vs. the 8-week ("standard") therapy in 471 Caucasian smokers with either normal or reduced rates of nicotine metabolism as determined at pretreatment. Extended therapy was superior to standard therapy in genotypic or phenotypic reduced metabolizers (RMs) of nicotine but not in normal metabolizers (NMs). RMs of nicotine are candidates for extended transdermal nicotine therapy, whereas an alternative therapeutic approach may be needed for those with normal rates of nicotine metabolism.
在一项安慰剂对照试验中，我们在 471 名白种烟民中研究了 6 个月（“延长”）经皮尼古丁疗法与 8 周（“标准”）疗法的疗效，这些烟民的尼古丁代谢率在治疗前被确定为正常或降低。对于尼古丁基因或表型代谢降低者（RM），延长疗法优于标准疗法，但对于正常代谢者（NM）则不然。尼古丁代谢降低者适合接受延长经皮尼古丁疗法，而对于尼古丁代谢率正常者，则可能需要另一种治疗方法。
